RESUMO
Background@#Endoscopic sinus surgery (ESS) is the main surgical approach in the treatment of chronic rhinosinusitis (CRS) after failure of medical treatment.@*Objective@#The goal of this study was to evaluate computed tomography (CT) findings associated endoscopic sinus surgery.@*Materials and Methods@#17-73 ages of 200 CRS patients who were operated endoscopic sinus surgery at department of ENT of First Central Hospital between November 2019 and November 2020, involved in this study. Subjects were divided into 2 groups: 1) CRS with NP 2) CRS without NP. CT changes were evaluated according to the Lund-Mackay, Hoover score, Hounsfield unit before and after surgery. Statistical analysis was performed with Stata 12.1.@*Result@#Of the total subjects analysed, 112(56%) were male and 88 (44%) were female. Average age of subjects was 38.4±13.9. Male: female gender ratio of patients was 1.27:1. @*Conclusion@#Endoscopic sinus surgery for CRS is effective according to the evaluation of Lund-Mackay, Hoover and Hounsfield unit, and it was statistically significant (p<0.0001).
RESUMO
BACKGROUND: The 2016 World Health Organization (WHO) classification of central nervous system (CNS) tumors has been modified to incorporate the IDH mutation and 1p/19q co-deletion in the diagnosis of diffuse gliomas. In this study, we aimed to evaluate the feasibility and prognostic significance of the revised 2016 WHO classification of CNS tumors in Mongolian patients with diffuse gliomas. METHODS: A total of 124 cases of diffuse gliomas were collected, and tissue microarray blocks were made. IDH1 mutation was tested using immunohistochemistry, and 1p/19q co-deletion status was examined using fluorescence in situ hybridization analysis. RESULTS: According to the 2016 WHO classification, 124 cases of diffuse brain glioma were reclassified as follows: 10 oligodendroglioma, IDHmut and 1p/19q co-deleted; three anaplastic oligodendroglioma, IDHmut and 1p/19q co-deleted; 35 diffuse astrocytoma, IDHmut, 11 diffuse astrocytoma, IDHwt, not otherwise specified (NOS); 22 anaplastic astrocytoma, IDHmut, eight anaplastic astrocytoma, IDHwt, NOS; and 35 glioblastoma, IDHwt, NOS, respectively. The 2016 WHO classification presented better prognostic value for overall survival in patients with grade II tumors than traditional histological classification. Among patients with grade II tumors, those with oligodendroglioma IDHmut and 1p/19q co-deleted and diffuse astrocytoma IDHmut showed significantly higher survival than those with diffuse astrocytoma IDHwt, NOS (p<.01). CONCLUSIONS: Mongolian diffuse gliomas could be reclassified according to the new 2016 WHO classification. Reclassification revealed substantial changes in diagnosis of both oligodendroglial and astrocytic entities. We have confirmed that the revised 2016 WHO CNS tumor classification has prognostic significance in Mongolian patients with diffuse gliomas, especially those with grade II tumors.